Drugs / E7820
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01773421 | Jun 2011 → Apr 2014 | cancer | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00078637 | Jan 2004 → Aug 2006 | lymphoma | Eisai Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01133990 | Mar 2010 → Feb 2011 | colorectal cancer | Eisai Inc. | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05024994 | Aug 2021 → Jun 2025 | acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00309179 | Sep 2007 → Dec 2009 | colorectal cancer | Eisai Inc. | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01347645 Comparator | Sep 2011 → Jun 2015 | colon carcinoma, rectal carcinoma | Eisai Inc. | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | E7820 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01347645 ↗ |
| Known as | ER-68203-00 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297376 ↗ |
| Modality | Small molecule | “an anti-cancer sulfonamide” PMID 37814121 ↗ Oct 2023 |
| Route | Oral | “After Oral Administration” NCT00078637 ↗ |
| Target | RBM39 | “degrades RBM39” PMID 37814121 ↗ Oct 2023 |